Our Shield™ blood test gains FDA approval, ushering in a new era of colorectal cancer screening.  More details

12/15/2022

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

Study demonstrates 83% sensitivity for detection of colorectal cancer with specificity of 90%

Back to Blog Listing

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.